MedWatch

Össur key market sales normalize during second quarter

Prosthetics manufacturer Össur has experienced significant improvements to its growth in Q2 2021, compared to the same period last year which was hugely affected by covid-19.

Photo: Össur / PR

Icelandic prosthetics firm Össur's key market sales have normalized during the second quarter of this year, with large growth achieved compared to the same period in 2020.

"Sales continued to normalize on our key markets, both within Prosthetics and Bracing & Supports. The sales growth during the second quarter was high, as the comparable period in 2020 was highly affected by covid-19," says Jon Sigurdsson, CEO of Össur, in the company's quarterly report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs